Executive summary
US Patent 10,683,343 claims (i) a plasma-derived immune globulin made from a large-donor pooled plasma input (≥500 donors) with specified RSV neutralization titer and defined donor-selectivity that boosts parainfluenza virus 1 and/or 2 antibody titers relative to a “control pool,” and (ii) broad downstream formulations (immune globulin + carrier) and methods of immunotherapy for treating or preventing specified viral infections in defined subject groups. The patent’s enforceability and practical value hinge on (a) whether the asserted product matches the pooling/titer/donor-percentage parameters, and (b) whether litigation can be proven at the manufacturing record level (pool selection, assay results, and donor inclusion percentages). The claim set is broad on permitted “carriers” and optionally includes other antibody specificities, but comparatively narrow on the key novelty anchor: the RSV-driven pool design plus a parainfluenza antibody uplift relative to a defined control sample.
H1: US Patent 10,683,343 claim chart and patent landscape for RSV and parainfluenza boosted pooled immune globulin
What does US Patent 10,683,343 claim and what is the novelty anchor?
Core protected invention (independent claim 1)
An immunotherapeutic composition comprising:
A. Immune globulin prepared from pooled plasma with:
- ≥500 human plasma donors
- pooled plasma has a final RSV neutralization titer ≥1800
- pooled plasma has an antibody titer for parainfluenza virus 1 and/or parainfluenza virus 2 that is ≥1.3× the antibody titer in a control sample defined as:
- mixture of plasma samples from ≥500 random donors
- <50% of those donors are from donors with final RSV neutralization titer ≥1800
B. pharmaceutically acceptable carrier
Key dependent claim dimensions
- Claim 2-4: optional anti-toxin agent (mono/bis/multi-specific toxin-binding antibodies), with example toxin scope including botulinum, tetanus, E. coli, C. difficile, Vibrio RTX, staphylococcal, cyanobacteria toxins, mycotoxins.
- Claim 5: optional additional antibody specificities including diphtheria, measles, polio.
- Claim 6-8: optional broad classes of biologically active agents (anti-inflammatory, anti-cancer, anti-microbial, antihistamine, cytokine, chemokine) and anti-inflammatory sub-classes.
- Claim 9-10: optional enhanced titer requirements for coronavirus OC43/229E and/or influenza A/B and/or metapneumovirus, each at ≥1.3× versus control.
- Claim 11: a specific numerical limitation: 30–45% of donors used for pooling have RSV neutralization titer ≥1800.
- Claims 12-19: broad method-of-use to administer the claimed composition to treat/prevent infection, including RSV, parainfluenza 1/2, OC43, 229E, influenza A/B, metapneumovirus, including reducing viral load, with subject groups including immunodeficiency and many clinical subtypes.
Novelty anchor in litigation posture
The defensible “fingerprint” is not “immune globulin from pooled plasma” alone; it is the pool-conditioning: a high-RSV neutralization titer (≥1800) coupled to a measurable parainfluenza antibody uplift (≥1.3× vs a defined control pool) and, in one dependent claim, a quantitative donor fraction (30–45% RSV-high donors).
That structure matters because an accused product could be plasma-derived immune globulin yet avoid infringement by:
- not meeting RSV neutralization ≥1800 at the final pooled-plasma stage,
- not meeting the ≥1.3× parainfluenza uplift relative to a defined control,
- changing the operational definition/assay comparators (challenging how “control sample” is generated and tested), or
- changing donor selection so the RSV-high donor fraction falls outside claim 11 (though claim 1 does not specify 30–45%).
What are the infringement-critical claim limitations in claim 1?
For infringement (and for designing a design-around), claim 1 can be decomposed into four “must-hit” elements.
1) Immune globulin made from pooled plasma with ≥500 donors
This is a manufacturing-input threshold. If an accused product’s upstream pool uses fewer than 500 donors, it avoids the literal scope. If it uses more, that element is typically satisfied.
2) Final RSV neutralization titer ≥1800 in the pooled plasma
This is a quantitative assay endpoint. In disputes, this often becomes the primary battleground: neutralization assay conditions, readouts, and lot-to-lot consistency.
3) Parainfluenza 1 and/or 2 antibody titer uplift ≥1.3× vs a “control sample”
This comparator is unusual. It defines the “control” as a mixture of ≥500 random donors where <50% are RSV-high donors (final RSV neutralization ≥1800). Proving this in litigation can require expert testimony on how the “control sample” is constructed for the accused product’s testing context.
4) Parainfluenza antibody assay identity and linkage to “pooled plasma composition”
The claim says antibody titer for parainfluenza 1 and/or 2. It does not specify assay type (ELISA vs neutralization vs binding). If the assayed antibody titer in the accused product is not measured on the same principle, infringement arguments could shift to claim construction.
When does US Patent 10,683,343 lose exclusivity for FDA reference products?
No answer can be produced from the information provided. Exclusivity in the US depends on the exact FDA product(s) the patent is listed against in the Orange Book and the patent listing strategy (drug substance vs drug product vs method-of-use) and on the patent’s expiration date (and any statutory adjustments). The claim text alone does not identify those elements.
What patent estate does US Patent 10,683,343 sit in, and how many related claims/patents likely exist?
No answer can be produced from the information provided. A credible landscape requires identifying:
- the application family and continuation set for US 10,683,343,
- priority dates and continuation claims,
- other US patents (and corresponding WO/EP/CN) in the same family, and
- whether the estate focuses on pooling parameters, assay endpoints, parainfluenza uplift, or expanded viruses.
Those determinations cannot be completed without bibliographic and prosecution record information.
What formulations are protected beyond immune globulin in US 10,683,343?
From the claim set provided, the formulation scope is broad at the “carrier” level but specific at the “immune globulin preparation” level.
Broad formulation elements
- “pharmaceutically acceptable carrier” is open-ended. This typically includes buffers, stabilizers, sugars, and excipients commonly used in immunoglobulin products.
Optional co-formulated actives
Claims 6–8 allow addition of a wide range of biologically active agents, including anti-inflammatory, anti-cancer, anti-microbial, antihistamine, cytokines, chemokines, and anti-inflammatory agents (recombinant antibodies, monoclonal antibodies, proteins, or small molecules).
Optional toxin-binding component
Claims 2–4 add an anti-toxin agent with toxin-binding specificity. This is expansive in the toy-box sense (many toxin examples) but it still requires “specificity toward a bacterial or fungal toxin” and (in claim 3) mono-/bi-/multi-specific antibody formats.
Practical implication
Most enforcement risk for competitors is likely tied to whether their pooled immune globulin itself meets the RSV+parainfluenza uplift manufacturing criteria. Co-formulation with other actives would increase design-around options, but claims 6–8 and 2–4 are optional additions; an accused immune globulin without anti-toxin or additional actives could still infringe claim 1/12 if the immune globulin preparation matches.
What method-of-use claims are included and what subject populations are covered?
Method claim 12 protects administering a therapeutically effective amount of the composition.
Population coverage (claims 13–15)
- immunodeficiency
- primary immunodeficiency disease (PIDD)
- includes ESRD, immunosuppressive therapy, AIDS, diabetes, neonates, transplant patients, malfunctioning immune system, elderly, autoimmune disease, burns, cancer, acute care setting
Indication coverage (claims 16–19)
- treat and/or prevent infection
- infections caused by: RSV, parainfluenza virus 1, parainfluenza virus 2, coronavirus OC43, coronavirus 229E, influenza A, influenza B, metapneumovirus
- respiratory infection use
- reduces viral load
Claim strategy effect
Method-of-use claims can be asserted against marketed products even if the product label does not mirror the claim’s subject-matter framing. In practice, plaintiffs often seek the narrowest interpretation that still matches clinical use and marketing. The breadth here makes it easier to map multiple patient settings into the claim language.
How does US 10,683,343 compare with conventional IVIG/immune globulin patent patterns?
Conventional IVIG patents often focus on:
- manufacturing processes (fractionation, inactivation steps),
- stabilization/formulation components,
- specific virus neutralization profiles as acceptance criteria, or
- method-of-use for immunodeficiency.
US 10,683,343’s differentiator is the pool design logic: a selected proportion of RSV-high donors drives a measurable parainfluenza antibody uplift relative to a defined random-donor control distribution. That creates a more direct nexus between immune globulin’s antiviral content and its upstream donor selection.
From a competitive standpoint, that also creates a clearer (but harder) test for infringement: assay-based pooling performance.
Which design-around strategies are most plausible against the claim language provided?
Based strictly on the provided claims, the highest-leverage options are:
-
Fail the RSV neutralization ≥1800 requirement
If the pooled plasma’s final RSV neutralization titer is below the threshold, the composition can avoid claim 1.
-
Preserve RSV but break the parainfluenza uplift comparator
If the pooled parainfluenza antibody titer does not reach ≥1.3× versus the claimed control comparator, literal infringement weakens.
-
Alter what counts as “control sample”
Because the claim defines the control as a mixture of ≥500 random donors with <50% RSV-high donors, a defendant may attempt to argue that the comparator must be generated in a particular way tied to the defendant’s donor database and assay platform. If the plaintiff cannot replicate the comparator, infringement can fail.
-
Use a pooled immune globulin with different donor thresholds
If the pool includes fewer than 500 donors, claim 1 is avoided. If it uses 500+ donors, that route narrows.
-
Exploit claim 11’s “30–45%” donor fraction
Claim 11 provides a numerical additional limitation. If an accused product is outside 30–45% RSV-high donors, it avoids claim 11, but not necessarily claim 1 unless the numerical fraction is required by claim construction.
What generic entry risks exist for immune globulin products under US 10,683,343?
No generic entry “risks” can be quantified without identifying:
- whether the covered product is IVIG / SCIg / IG,
- whether it is FDA-reviewed as a biologic with a particular reference product,
- whether any biosimilar applicants exist, and
- whether US 10,683,343 is listed in the Orange Book for that product (or whether there are BLA exclusivity or 351(k) regulatory pathways impacting timing).
What litigation and settlement events affect enforcement risk for US 10,683,343?
No answer can be produced from the information provided. Litigation posture depends on PACER and trial dockets tied to the patent number, including whether US 10,683,343 is asserted alone or bundled with related patents, and whether any settlements create covenants or licensing structures.
What is the Orange Book status of US 10,683,343?
No answer can be produced from the information provided. Orange Book status requires mapping the patent to FDA-listed drugs, listing codes, and associated active ingredient(s) and dosage forms.
Key claim-by-claim risk map for a competitor building an accused immune globulin
| Claim |
High-level protection |
Most likely infringement-critical variable |
Best design-around lever |
| 1 |
Immune globulin from ≥500 donor pooled plasma with RSV-neutralization ≥1800; parainfluenza 1/2 antibody titer ≥1.3× vs defined control |
RSV neutralization assay and parainfluenza antibody uplift vs comparator |
Lower RSV titer; reduce uplift; challenge control comparator construction |
| 2 |
Claim 1 + anti-toxin agent |
Whether composition includes toxin-binding antibody |
Exclude anti-toxin agent |
| 3 |
Claim 2 with mono-/bi-/multi-specific toxin antibodies |
Antibody format and toxin specificity |
Use different modality or toxin specificity |
| 4 |
Claim 3 with toxin examples |
If toxin selection is mapped to claim language |
Avoid matching toxin list or challenge “selected from” interpretation |
| 5 |
Claim 1 + added antibody specificities |
Additional titer profiles (diphtheria/measles/polio) |
Exclude matching specificities or argue titer failure |
| 6 |
Claim 1 + biologically active agent class |
Presence/type of added agent |
Omit added agent class |
| 7-8 |
Claim 1 + immunotherapeutic / anti-inflammatory agent types |
Presence/type of added agent |
Omit or use excluded type |
| 9 |
Claim 1 + coronavirus OC43/229E uplift ≥1.3× |
Coronavirus antibody titer uplift vs control |
Fail uplift requirement or omit relevant titers |
| 10 |
Claim 1 + influenza A/B and/or metapneumovirus uplift ≥1.3× |
Influenza/metapneumovirus antibody titer uplift vs control |
Fail uplift or omit |
| 11 |
Claim 1 + 30–45% RSV-high donors |
Donor fraction in pool |
Move fraction outside 30–45% |
| 12-19 |
Administering composition for specified infections and populations |
Whether therapy and dosing are used for covered indications |
Avoid covered indications/patient populations; argue composition mismatch |
Business implications for licensing, investment, or R&D
- The patent’s enforceability is likely tied to manufacturing batch analytics: RSV neutralization titer at the pooled-plasma stage and parainfluenza antibody titers relative to a comparator.
- For licensors or investors, the key diligence item is whether the pool-conditioning parameters can be validated and replicated across lots and time. A competitor with transparent donor selection and consistent viral titers can create a stronger infringement record.
- For R&D teams, the claim set suggests the “sweet spot” in avoidance: keep immune globulin manufacture conventional but avoid the claimed RSV-high donor fraction and especially avoid the ≥1.3× parainfluenza uplift relative to the defined control scenario.
Key Takeaways
- US 10,683,343 is centered on a plasma donor pooling design: RSV-high pooled plasma (final RSV neutralization ≥1800) that yields a parainfluenza 1/2 antibody uplift ≥1.3× vs a defined “random donor” control pool.
- The claims are broad on carriers and optional co-actives, but narrow on the titer-conditional manufacturing fingerprint.
- Method-of-use claims cover a wide patient and infection set and include reducing viral load.
- The main infringement risk for competitors is failing to design around the assay thresholds and comparator construct, not co-formulation or carrier selection.
FAQs
1) Can immune globulin infringe if it meets RSV neutralization ≥1800 but not the 1.3× parainfluenza uplift?
No, based on the claim language, the parainfluenza antibody uplift requirement is a necessary limitation for claim 1.
2) Does claim 11 (30–45% RSV-high donors) control infringement for claim 1?
Claim 11 is a dependent limitation. It can matter if asserting claim 11 specifically, but claim 1 does not require the 30–45% fraction as written.
3) What happens if an accused product lacks parainfluenza 1/2 antibody titer measurements?
If infringement is litigated, the plaintiff must establish the claimed titer outcomes for the accused pooled plasma/lot. Lack of matching results can be outcome-determinative.
4) Are coronavirus OC43/229E and influenza/metapneumovirus requirements mandatory for all covered compositions?
No. Claims 9 and 10 add additional optional titer uplift limitations. Claim 1/12 do not require them.
5) Do the subject population and infection indications automatically create infringement for any immune globulin administration?
No. Infringement under method claims requires both the composition and the therapeutic use fitting the claim language (infection type and subject group as claimed).
References (APA)
- Claims of US Patent 10,683,343 provided in prompt.
